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Cell-free microRNAs in plasma and serum have become a promising source of biomarkers
for various diseases. Despite rapid progress in this field, there remains a lack of consensus
regarding optimal quantification methods, reference genes, and quality control of samples.
Recent studies have shown that hemolysis occurring during blood collection has substan-
tial impact on the microRNA content in plasma/serum.To date, the impact of hemolysis has
only been investigated for a limited number of microRNAs, mainly the red blood cell (RBC)-
enriched miRs-16 and -451. In contrast, the effect of hemolysis on other microRNAs – in
particular those proposed as biomarkers – has not been addressed. In this study we profiled
the microRNA content of hemolyzed and non-hemolyzed plasma as well as RBCs to obtain
a profile of microRNAs in the circulation affected or unaffected by hemolysis. Profiling by
TaqMan Array Microfluidic Cards was used to compare three pairs of hemolyzed and non-
hemolyzed plasma (with varying degrees of hemolysis) and one RBC sample. A total of 136
microRNAs were detectable in at least two of the samples, and of those 15 were at least
twofold elevated in all three hemolyzed samples.This number increased to 88 microRNAs
for the sample with the highest level of hemolysis, with all of these also detected in the
RBC profile.Thus these microRNAs represent a large proportion of detectable microRNAs
and those most likely to be affected by hemolysis. Several of the hemolysis-susceptible
microRNAs (e.g., miRs-21, -106a, -92a, -17, -16) have also been previously proposed as
plasma/serum biomarkers of disease, highlighting the importance of rigorous quality con-
trol of plasma/serum samples used for measurement of circulating microRNAs. As low-level
hemolysis is a frequent occurrence during plasma/serum collection it is critical that this is
taken into account in the measurement of any candidate circulating microRNA.
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INTRODUCTION
Since the discovery that microRNAs are not only present within
cells, but can also be detected extracellularly in a variety of body
fluids, a large number of studies have investigated the potential
use of these cell-free microRNAs as diagnostic and/or prognos-
tic biomarkers (Reid et al., 2011; Creemers et al., 2012; Mo et al.,
2012). Unlike their longer mRNA counterparts which are prone
to degradation in body fluids as a result of the high content of
RNase particularly in blood, microRNAs are surprisingly stable.
This increased stability of microRNAs can be attributed to: (i) their
encapsulation into microvesicles such as exosomes and apoptotic
bodies (Cortez and Calin, 2009; Kosaka et al., 2010) and (ii) their
association with protein complexes such as argonaute 2 (Arroyo
et al., 2011; Turchinovich et al., 2011) and high density lipoprotein
(Vickers et al., 2011).
Being easily accessible and collected routinely as part of medical
assessments, plasma and serum represent the most promising and
best studied sources of cell-free microRNAs. While a large number
of studies have aimed to identify microRNAs in plasma or serum
that can serve as biomarkers for disease, there is still a lack of
consensus regarding optimal quantification methods, appropriate
reference genes as well as quality assurance and quality control of
samples.
Of particular relevance to the identification of cell-free
microRNA-based biomarkers in blood, a small number of stud-
ies have recently shown that rupturing of red blood cells (RBCs)
occurring most often during blood collection or sample process-
ing can have substantial impact on the levels of certain microRNAs
detectable in plasma and serum (Kirschner et al., 2011; McDonald
et al., 2011; Pritchard et al., 2012). These studies only investi-
gated the effect of hemolysis on a very limited number of cell-free
microRNAs, in particular miR-16 and miR-451, but serve as a
first indication and warning that hemolysis can significantly alter
the levels of microRNAs in plasma and serum. It is not surpris-
ing that the levels of miR-16 and miR-451 vary depending on
the degree of hemolysis given they represent two of the most
abundant microRNAs in RBCs (Bruchova et al., 2007; Vasilatou
et al., 2010). However, our own data (Kirschner et al., 2011) and
those of Pritchard et al. (2012) also revealed that levels of miR-
92a, a microRNA proposed as a potential biomarker for ischemic
heart disease (Fichtlscherer et al., 2010) and various cancer types
(Tanaka et al., 2009; Huang et al., 2010; Ohyashiki et al., 2011)
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are also affected by hemolysis. In addition, Blondal et al. (2013)
have recently reported on 119 microRNAs measured in high qual-
ity and compromised (general blood cell contamination) serum
samples. This study showed that in samples with blood cell conta-
mination many of those 119 microRNAs significantly deviate from
the mean expression levels observed in 381 high quality samples
used as comparator. Together, these observations raise the possi-
bility that other potential biomarkers could be equally impacted
by hemolysis.
In the present study we profiled the microRNA content of non-
hemolyzed and hemolyzed plasma as well as RBCs to identify those
microRNA most likely to be affected by hemolysis.
MATERIALS AND METHODS
BLOOD COLLECTION
Blood was collected from consenting patients [with either malig-
nant pleural mesothelioma (MPM) or coronary artery disease
(CAD)] and healthy controls from the antecubital fossa using a
butterfly device (21 G, BD Bioscience). A total of four 4 ml or
three 10 ml K3EDTA Vacutainer Plus Tubes (BD Biosciences) was
taken in one collection. Written informed consent was obtained
from all participants and the study was approved by the Human
Research Ethics Committee at Concord Repatriation General and
Royal Prince Alfred Hospitals, Sydney, Australia. Within 60 min
of blood collection samples were subjected to centrifugation at
2500 g for 20 min at room temperature. Plasma supernatant was
removed leaving at least a 500µl layer behind to avoid disturb-
ing the buffy coat layer. Samples were frozen as 500µl aliquots
and stored at −80˚C until further use. Purified RBCs from one
healthy donor were obtained by separation of blood components
using Ficoll-Paque PLUS according to the manufacturer’s recom-
mendations. The dilution series used in this study was the same as
published previously (Kirschner et al., 2011). Table 1 summarizes
patient/volunteer demographics and identifies how samples were
used in profiling and validation.
We observed that blood collection of single patients sometimes
resulted in plasma with hemolysis occurring in one or two of
the collection tubes while the plasma in the remaining tube(s)
was non-hemolyzed. The hemolyzed sample of the matched pairs
used in this study was the result observed after standard collection
procedure, and was not induced chemically or physically.
Hemolysis in the dilution series was achieved by addition of
lysed RBCs (freeze-thawed and mixed by continuous vortexing for
60 s) to non-hemolyzed plasma from the healthy volunteer. Ser-
ial dilution from this 2% RBC sample was performed to obtain
the samples used in this study, as described (Kirschner et al.,
2011). Two independent dilution series using plasma from two
independent blood collections were prepared.
ASSESSMENT OF HEMOLYSIS
The level of hemolysis in plasma samples was assessed by spec-
trophotometry (NanoPhotometer P300, Implen) with readings
at wavelengths scanning from 350 to 650 nm. The degree of
hemolysis was determined based on the optical density at 414 nm
(absorbance peak of free hemoglobin), with additional peaks
occurring at 541 and 576 nm being indicative of very high levels
of hemolysis. Samples were classified as being hemolyzed if the
A414 reading exceeded a valued of 0.2 as we have previously shown
that excluding samples with higher A414 significantly decreases the
variability of miR-16 and miR-451 (microRNAs highly abundant
in RBCs) within a sample series (Kirschner et al., 2011). Based
on our experience non-hemolyzed samples present with an A414
reading between 0.14 and 0.18. See Table 2 for A414 measurements
of all samples used in this study.
RNA ISOLATION
Total RNA was isolated from 400µl of plasma from six individu-
als for whom non-hemolyzed and hemolyzed plasma obtained
from different collection tubes but the same blood collection
was available. In addition RNA was isolated from 100µl Ficoll-
purified RBCs from the healthy donor and from 400µl of plasma
containing RBC dilution [5 points of a serial dilution series
(Kirschner et al., 2011)]. RNA isolation was performed using
the mirVana PARIS miRNA isolation Kit (Life Technologies)
with small modifications. The RBC samples were mixed with
300µl cell disruption buffer prior to further processing identi-
cal to the plasma samples. Following the denaturing step of the
isolation process, 100µg mussel glycogen (Roche) were added
to each sample as carrier to enhance isolation efficiency. After
separation and recovery of the aqueous phase, a second phenol–
chloroform extraction of the aqueous phase was included to
improve the removal of the high protein content of plasma. Fol-
lowing the column-purification part, RNA was eluted using 100µl
ultrapure H2O (95˚C), resulting in a recovery of around 85µl
RNA. For each sample two independent RNA isolations were
performed.
Table 1 | Patient/volunteer demographics and use of samples in this study.
Sample ID Gender Age Diagnosis Profiling Validation
N1* F 31 N/A No Yes
N2* F 31 N/A Yes Yes
MPM1 M 64 Sarcomatoid malignant mesothelioma Yes Yes
CAD1 M 79 Stable coronary artery disease Yes Yes
CAD2 M 65 Stable coronary artery disease No Yes
CAD3 M 80 Stable coronary artery disease No Yes
*N1 and N2 are the same individual with samples obtained from two independent collections (2months apart) which both resulted in collection of 1 hemolyzed and
1 non-hemolyzed plasma sample with different degrees hemolysis. Blood for the dilution series was collected from the same individual.
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Table 2 | Free hemoglobin measurements for matching sample pairs
and dilution series.
Sample A414 Degree of hemolysis
relative to
non-hemolyzed
Non-hemolyzed Hemolyzed
N1 0.174±0.015 0.413±0.062 2.36±0.16
N2 0.153±0.015 0.412±0.039 2.68±0.003
MPM1 0.124±0.014 0.558±0.01 4.53±0.58
CAD1 0.184±0.028 0.25±0.025 1.37±0.07
CAD2 0.127±0.008 0.242±0.012 1.90±0.01
CAD3 0.143±0.03 0.574±0.129 4.01±0.06
0.0% RBC 0.143±0.013 N/A N/A
0.008% RBC 0.184±0.001 1.29±0.13
0.016% RBC 0.245±0.042 1.73±0.45
0.031% RBC 0.321±0.057 2.28±0.61
0.0625% RBC 0.420±0.036 2.96±0.52
0.125% RBC 0.626±0.019 4.39±0.27
For those samples to be used for microRNA profiling 70µl of
the total RNA were further concentrated in order to increase the
amount of RNA that could be reverse transcribed. These samples
were mixed with 300 mM sodium acetate pH 5.2, 2.5 ng mus-
sel glycogen, and 175µl 100% Ethanol and incubated over night
at −80˚C. RNA was precipitated by centrifugation at 17000 g
for 20 min at 4˚C. Pellets were washed with 1 ml 75% Ethanol
and re-precipitated at 17000 g for 10 min at 4˚C. After removal
of the supernatant RNA was air-dried for approximately 10 min
(until the RNA pellet changed color from white to opaque) and
then resuspended in 10µl ultrapure H2O. RNA concentration
was assessed using the Qubit RNA Assay Kit (Life Technologies),
however RNA concentrations for the plasma samples were below
the limits of detection. All samples were stored at −80˚C until
further use.
TaqMAN ARRAY MICROFLUIDIC CARD microRNA PROFILING
MicroRNA profiling was performed using the TaqMan Array
Human MicroRNA A+B Cards Set v3.0 together with the
Megaplex™RT Primers, Human Pool Set v3.0 (Life Technologies)
following the protocol for profiling without pre-amplification.
The profiling was performed twice using two independent
isolations of matching non-hemolyzed and hemolyzed plasma
pairs from three individuals. Each RNA sample was reverse tran-
scribed using each the A and B Megaplex Primer Pools. Briefly,
3µl precipitated RNA was mixed with 1× reaction buffer, 3 mM
MgCl2, 2 U RNase Inhibitor, 2.7 mM dNTPs, 1× Megaplex Primer
Pool A or B, and 75 U MultiScribe Reverse Transcriptase under
the following reaction conditions: 40 cycles of 2 min annealing
at 16˚C, complimentary DNA (cDNA) synthesis for 1 min at
42˚C and 1 s at 50˚C, followed by denaturing for 5 min at 85˚C.
The obtained cDNA was then stored at −20˚C for use within
1 week.
Six microliters cDNA were mixed with 444µl ultrapure H2O
and 450µl 2×TaqMan Gene Expression Master Mix and 100µl of
this mix were loaded into each port of the corresponding Microflu-
idic Array card according to the manufacturer’s instructions. Array
cards were then run on a ViiA 7 Real-Time instrument (Life Tech-
nologies) with 2 min UDG incubation at 50˚C and 10 min enzyme
activation at 95˚C followed by 40 cycles of 15 s denaturation at
95˚C and 60 s annealing/elongation at 60˚C.
Quantification cycle (Cq) values were determined using
the ViiA 7 Software v1.2 applying a fixed threshold
level of 0.05. Data were then analyzed using the 2−∆Cq
method (Livak and Schmittgen, 2001; Schmittgen and Livak,
2008) expressing levels of microRNAs in hemolyzed sam-
ples relative to those in non-hemolyzed samples without nor-
malization to an endogenous control: relative expression=
2−((Cqtarget(Hemolyzed))− (Cqtarget(Non-Hemolyzed))). Alternatively,
direct comparisons were performed at the level of raw Cq values.
MicroRNAs with Cq value >35 in every sample analyzed were
excluded from analysis.
INDIVIDUAL microRNA REVERSE TRANSCRIPTION REAL-TIME
QUANTITATIVE PCR
Levels of selected microRNAs were assessed using Taq-
Man microRNA Assays. Reverse transcription (RT) was per-
formed using microRNA-specific stem-loop RT primers and the
MicroRNA RT Kit (both Life Technologies). A fixed volume of
1.67µl total RNA was used as template in the RT reaction, and
combined with 4µl of an equimolar mix of 7 or 8 microRNA-
specific primers (consisting of 31.25 nM of each specific primer),
1 nM dNTPs, 2.4 U RNase Inhibitor, 33 U MultiScribe reverse tran-
scriptase, and RNase-free water in a total volume of 10µl. RT
primer mix 1 consisted of primers for miR-122 (ID 002245), -142-
3p (ID 000464), -146a (ID 000468), -16 (ID 000391), -486-3p (ID
002093), -532-3p (ID 002355), -636 (ID 002088), and -886-5p (ID
002193), mix 2 contained primers for miR-1255B (ID 002801),
-1274B (ID 002884), -15b (ID000390), -16, -451 (ID 001105),
-625-3p (ID 002432), and RNU48 (001006), mix 3 consisted of
miR-103 (ID 000439), -106a (ID 002169), -126 (ID 002228), -17
(ID 000393), -27a (ID 000408), -29a (ID 002112), and -92a (ID
000431), and mix 4 contained miR-155 (ID 002623), -16, -21 (ID
000397), 210 (ID 000512), -223 (002295), -31 (ID 002279), and
-720 (ID 002895). Reaction conditions followed the manufac-
turer’s instructions: annealing for 30 min at 16˚C, followed by
cDNA synthesis for 30 min at 42˚C and denaturing for 5 min at
85˚C. The resultant cDNA was diluted by addition of 57.8µl water
and used immediately in qPCR or stored at−20˚C.
For real-time qPCR detection of microRNAs, 2.25µl of the
diluted cDNA were used as template in reactions containing 1×
microRNA-specific TaqMan primers/probes (see above for assay
IDs) in combination with 1×TaqMan GeneExpression MasterMix
(both Life Technologies) according to the manufacturer’s instruc-
tion in a total reaction volume of 10µl, with the following reaction
conditions: 2 min UDG incubation at 50˚C and 10 min enzyme
activation at 95˚C followed by 40 cycles of 15 s denaturation at
95˚C and 60 s annealing/elongation at 60˚C. No-template sam-
ples were included as negative controls. Duplicate qPCR reactions
were set up manually and run on a ViiA 7 Real-Time Instrument
(Life Technologies). Cq values were determined using the ViiA 7
Software v1.2 applying a fixed threshold level of 0.05. In case of
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matched pairs of non-hemolyzed and hemolyzed plasma, relative
abundance in the hemolyzed samples as compared to the non-
hemolyzed sample was calculated using the 2−∆Cq method (Livak
and Schmittgen, 2001; Schmittgen and Livak, 2008) as described
above. Data for the dilution series are presented as raw Cq values
for each microRNA.
All raw Cq data (average of duplicates) are provided in Tables
1 (profiling) and 2 (validation) in Supplementary Material. Mini-
mum Information for Publication of Quantitative Real-Time PCR
Experiments (MIQE) guidelines (Bustin et al., 2009) were followed
for description of samples, RNA extraction, RT, qPCR protocol,
and data analysis.
RESULTS
PROFILING MATCHED HEMOLYZED AND NON-HEMOLYZED PLASMA
SAMPLES IDENTIFIES microRNAs AFFECTED BY HEMOLYSIS
In order to better understand the contribution of hemolysis to the
levels of microRNAs in plasma, we profiled the microRNA content
of three matched pairs of non-hemolyzed and hemolyzed plasma
and one RBC sample from the healthy donor.
The number of microRNAs detected with a Cq< 35 in each
sample varied between 91 and 194, as did the number of
microRNAs affected by hemolysis (Figure 1A). We further fil-
tered these microRNAs, identifying a total of 136 microRNAs that
were detectable in at least 4 of the 6 plasma samples profiled and,
with the exception of the liver-specific miR-122, all of these were
also detected in the RBC sample. Relative expression levels of
those 136 microRNAs in the hemolyzed sample as compared to
the non-hemolyzed counterpart are pictured in Figure 1B. This
shows that the majority of detectable microRNAs are elevated
in hemolyzed samples (represented by red color), while only a
handful of microRNAs are present at lower levels in hemolyzed
plasma (blue). The heat map further shows that there is a general
trend toward a correlation of higher levels of hemolysis-susceptible
microRNAs with the degree of hemolysis.
Further analysis identified that of the microRNAs detected in
plasma, 15 (11%, the center of the Venn diagram in Figure 1C)
demonstrated >2-fold higher levels in the hemolyzed samples of
all three pairs investigated. The number of elevated microRNAs in
hemolyzed compared to non-hemolyzed plasma increased to 52
(38.2%) microRNAs when including those only elevated in two
of the three pairs and to a total of 88 (64.7%) microRNAs being
elevated >2-fold in at least one of the pairs. Those microRNAs
identified as being significantly altered in only one of the pairs
were generally also altered in the other pairs, but did not show
increases above the selected threshold of at least twofold. Of the
microRNAs detectable only 11 appeared to be truly unaffected
by hemolysis and did not vary by more than ±1.5-fold in any
of the investigated pairs. Our profiling studies also identified
3 microRNAs (miR-1255B, miR-636, miR-886-5p) and a small
nucleolar RNA (snoRNA, RNU48) which were only present in
RBCs and hemolyzed plasma. While additional microRNAs were
found to be present only in RBCs and one or two of the hemolyzed
samples, these were not subject to further validation due to Cqs
being>35. Figure 2 provides an overview of all microRNAs which
increased in relative abundance by more than twofold following
hemolysis as well as those unaffected by hemolysis.
CHANGES OF SELECTED microRNAs WITH INCREASING RBC
CONTAMINATION
Our profiling data suggested that the levels of a number of
microRNAs detected in plasma increased with hemolysis. To fur-
ther investigate the contribution of RBC microRNAs to plasma
levels, we measured the levels of selected microRNAs in a series of
5 RNA samples obtained from a serial dilution of RBCs in non-
hemolyzed plasma (Kirschner et al., 2011) and six matched pairs
of non-hemolyzed and hemolyzed plasma (the three pairs used
for profiling +3 more). We quantified two microRNAs affected
by hemolysis (miR-486-3p, miR-532-3p), three not affected by
hemolysis (miR-1274B, miR-142-3p, miR-146a), and the four
microRNAs/snoRNAs only present in RBCs and hemolyzed
plasma (miR-1255B, miR-636, miR-886-5p, RNU48). In addition
we included miR-16, miR-15b, and miR-451 as miRs previously
shown to be affected by hemolysis as well as the liver-specific
miR-122.
Using our RBC dilution series, we observed an increase in Cq
values for miR-16, miR-451, and miR-15b with increasing RBC
concentration (Figure 3A), consistent with previously published
data (Kirschner et al., 2011; McDonald et al., 2011). In addi-
tion, we observed a considerable decrease in Cq (and therefore
an increase in abundance) with increasing RBC contamination
for the hemolysis-susceptible microRNAs miR-486-3p and miR-
532-3p identified from the profiling (Figure 3B). Similarly, levels
of miRs-1255B, -636, -886-5p, and RNU48, microRNAs/snoRNAs
identified as being RBC- and hemolysis-specific, also increased
with increasing RBC content (Figure 3C). In contrast levels
of those microRNAs identified as being the most stable (miR-
142-3p, miR-146a, and miR-1274B), as well as the liver-specific
miR-122 did not change with increasing RBC concentration
and showed only minor variability with <1.1 cycles between
the highest and lowest Cq for any of those miRs (Figure 3D;
Table 3).
When measuring levels of these microRNAs in matched pairs
of non-hemolyzed and hemolyzed plasma, we found a similar
pattern to that observed in the dilution series. The microRNAs
shown to be influenced by RBC content of the sample – miR-16,
-451, -15b, 486-3p, 532-3p, -886-5p, 636, -1255B, and RNU48 –
were up to 13-times more abundant in the hemolyzed sample as
compared to its non-hemolyzed counterpart (Figure 4A). In addi-
tion this increase in abundance was correlated with the degree of
hemolysis observed for the corresponding sample. MicroRNAs
identified as being unaffected by hemolysis showed only minor
variation (<±1.5-fold difference) in relative expression between
hemolyzed and non-hemolyzed plasma (with the exception of
CAD3) (Figure 4B).
IMPACT OF HEMOLYSIS ON PROPOSED BIOMARKER CANDIDATES
Following validation of the microRNAs selected from our profil-
ing studies, we investigated the effect of hemolysis on microRNAs
previously proposed as biomarkers for disease (Table 4). These
microRNAs included those for which the profiling suggested an
influence of hemolysis (miR-103, -106a, 17, -21, -210, -27a, -31,
-625-3p, -92a) as well as those unaffected by RBC contamination
(miR-122, -126, -146a, -155, -223, -29a, -720). Measurement in
the dilution series confirmed that microRNAs miR-106a, miR-17,
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FIGURE 1 | MicroRNA profiling of hemolyzed and non-hemolyzed
plasma. (A) Summary of each pairs microRNA profile, representing the
total number of microRNAs detectable as well as numbers of
microRNAs affected or unaffected by hemolysis in each pair. (B)
Heatmap of relative abundance of 136 microRNAs in hemolyzed
compared to non-hemolyzed plasma. Levels of microRNAs in
hemolyzed samples are presented as log2 of the relative expression
level (non-hemolyzed=0), with ±3.3 being the equivalent of a ±10-fold
difference in relative abundance. The microRNAs presented are those
detectable in at least four out of the six plasma samples investigated.
(C) Overlap of microRNAs increased >2-fold in each of the three pairs.
Fifteen microRNAs (inner triangle) were >2-fold increased in all three
investigated pairs, and an additional 37 microRNAs were >2-fold
increased in at least two of the investigated pairs.
miR-92a, and miR-210 are significantly affected by the level of
RBC contamination of the sample displaying decreases in Cq val-
ues of 1.5–2.4 cycles between 0 and 0.125% RBC contamination
(Figure 5A). This was also confirmed when looking at the matched
pairs in which those miRs were in most cases at least twofold
higher in the hemolyzed sample (Figure 5B). In addition miR-21
seemed to be affected by high degrees of hemolysis (Figure 5B).
Although miR-31 levels appear to be higher in hemolyzed com-
pared to non-hemolyzed plasma, this variability could be a result
of the low expression of this microRNA, with Cq values being
>34 in all samples. None of the remaining microRNAs showed
a correlation between Cq values and the degree of hemolysis
(Figures 5C,D).
IDENTIFICATION OF microRNA SUBSETS DISPLAYING SIMILAR
CHANGES DUE TO HEMOLYSIS
The clear influence of hemolysis on plasma microRNA content
raises the question of whether hemolyzed samples can be included
in biomarker discovery studies. To further address this issue we
interrogated the profiling data in an attempt to identify groups of
microRNAs with similar patterns of hemolysis-induced increase
with the aim of identifying subsets of microRNA from which
both endogenous controls and potential biomarkers could be
derived. For the purpose of this part of the study we focused
on the two samples exhibiting extensive hemolysis. Twenty-six
microRNAs were increased by at least twofold, in these sam-
ples with increases following the degree of hemolysis (Table 5).
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Similarly, we identified a second subset of 19 microRNAs which
varied by <±1.5-fold (Table 5). Both groups include microRNAs
previously proposed as biomarkers for disease. Although requir-
ing further validation, these two subsets represent groups of
microRNAs that may be used for selection of biomarker candi-
date(s) and endogenous control(s) potentially enabling hemolyzed
samples to be included in biomarker discovery studies.
FIGURE 2 | Continued
FIGURE 2 | Overview of microRNAs identified as being elevated in
hemolyzed plasma or unaffected by hemolysis. The top 15 microRNAs
are elevated in the hemolyzed sample of all three pairs, the following 37
microRNAs are elevated in two of the three pairs followed by the 36
microRNAs elevated in just one pair. The 11 microRNAs at the bottom of the
list represent those with less than ±1.5-fold difference between the
hemolyzed and non-hemolyzed sample.
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FIGURE 3 | RT-qPCR validation of candidates in dilution series of RBCs in
plasma. (A) Previously identified hemolysis affected microRNAs (B)
additional hemolysis affected microRNAs (C) RBC- and hemolyzed plasma
specific microRNAs (D) unaffected microRNAs. Data are presented as raw Cq
value±SD obtained from measurements in RNA isolated from two
independent dilution series.
Table 3 | Cq values of stable miRs in dilution series.
RBC concen-
tration (%)
miR-1274B miR-142-3p miR-146a miR-122
0.0 24.73±0.29 24.33±0.15 25.82±0.06 28.28±0.56
0.008 25.00±0.85 24.55±0.34 26.02±0.08 28.59±0.62
0.016 24.94±0.54 24.34±0.14 26.01±0.08 28.78±0.86
0.031 24.70±0.24 23.86±0.12 25.84±0.21 28.18±0.28
0.0625 24.65±0.49 23.65±0.08 25.80±0.05 28.29±0.37
0.125 24.82±0.20 23.55±0.80 26.00±0.31 28.63±0.82
DISCUSSION
Cell-free microRNAs are detectable in a variety of body fluids
and have in recent years attracted a lot of attention due to their
potential use as biomarkers for disease. The majority of studies
have focused on plasma or serum, attractive because it is readily
available, can be collected with minimal risk or discomfort and is
routinely collected as part of clinical assessment of patients. As a
result a large number of novel plasma or serum microRNA bio-
markers have been suggested in the last 5 years (Brase et al., 2010;
Reid et al., 2011; Creemers et al., 2012; Mo et al., 2012). Neverthe-
less, despite this rapid growth the field still suffers from a lack of
standardized and detailed reporting methods.
The cellular origin of most microRNAs detectable in the cir-
culation is as yet unknown. Studies comparing the microRNA
profile of plasma or serum from healthy and diseased individuals
(Chen et al., 2008; Kirschner et al., 2012) have shown that there is
extensive overlap between the profiles suggesting that many of the
microRNAs present in the circulation could play important roles
in the normal functioning of the circulatory and immune sys-
tem. Consequently, proposed markers for disease rarely seem to be
tissue-specific, making their use as markers for specific conditions
difficult. Examples of such microRNAs are miR-92a [proposed as
a diagnostic marker for colorectal cancer (CRC) (Huang et al.,
2010), and Non-Hodgkin’s Lymphoma (Ohyashiki et al., 2011),
as well as CAD (Fichtlscherer et al., 2010)] and miR-21 [e.g., in
gastric cancer (Tsujiura et al., 2010; Li et al., 2012), CRC (Kanaan
et al., 2012) and Non-small cell lung cancer (NSCLC) (Tang et al.,
2013)]. Assessment of the true role of these microRNAs is further
complicated by the high abundance of these and other microRNAs
in blood cells, and by variations in blood cell counts that have
been shown to have a significant impact on the levels detectable in
plasma or serum (Duttagupta et al., 2011; Pritchard et al., 2012).
The influence of blood cell lysis on plasma and serum levels
of microRNAs has until recently been neglected. While it had
already been reported that lymphocytes and RBCs have specific
microRNA content (Ramkissoon et al., 2006; Bruchova et al., 2007;
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FIGURE 4 | Validation of microRNAs in matching pairs. (A) microRNAs
changing with hemolysis (B) microRNAs not affected by hemolysis. Data are
presented as relative microRNA level±SD in the hemolyzed compared to the
non-hemolyzed sample value obtained from measurements in RNA from two
independent isolations per sample. The red line represents the relative
expression of the corresponding non-hemolyzed samples.
Collino et al., 2010; Vasilatou et al., 2010), the overlap between
these profiles and those in plasma were initially overlooked. In
2011, after 3 years of biomarker discovery studies, the first reports
describing the effects of hemolysis occurring during blood col-
lection or processing appeared, and suggested that this can have
considerable impact on the levels of certain microRNAs detected
in hemolyzed samples (Kirschner et al., 2011; McDonald et al.,
2011; Pritchard et al., 2012). The three studies all identified miR-
16 and miR-451 as being the most highly abundant microRNAs in
RBCs, and found levels of these microRNAs in plasma to be most
affected by hemolysis. In addition to the contribution of RBCs
to the cell-free microRNA profile, Pritchard et al., also showed
that platelet-derived microRNAs can significantly vary between
samples. Most studies highlighting the problems associated with
hemolysis have not yet gone beyond investigating small numbers of
microRNAs (in particular miR-16 and miR-451), but two reports
have already identified that miR-92a (a putative biomarker in sev-
eral cancers) is heavily affected by hemolysis (Kirschner et al.,
2011; Pritchard et al., 2012). In addition a recent study by Blondal
et al. (2013) has compared levels of 119 microRNAs in high qual-
ity serum/plasma and compromised serum/plasma. This study
has shown that the levels of many of those microRNAs deviate
significantly from the average level observed in a large number of
high quality samples when being measured in a compromised
sample with high blood cell contamination. Furthermore, this
study suggested the use of a ratio between a microRNA known
to be highly variable with hemolysis (miR-451) and a microRNA
found to be unaffected by hemolysis (miR-23a) as an indicator
for hemolysis, especially in a situation where only RNA is avail-
able while the original plasma/serum sample is unavailable for
assessment of hemolysis (Blondal et al., 2013).
To build on these observations and to further investigate the
effect hemolysis has on proposed cell-free microRNA biomarker
candidates we performed a more comprehensive comparison of
the microRNA content in hemolyzed and non-hemolyzed plasma.
This revealed up to 65% (88 of 136) of the microRNAs detectable
in plasma to be elevated in hemolyzed samples (Figure 2). Among
those were many microRNAs that have been previously proposed
as biomarkers for various diseases (Table 4), and upon vali-
dation we demonstrate that in addition to miR-16, -451, and
92a, levels of miRs-106a, -17, -21, and -210 were susceptible
to hemolysis (Figures 4A,B). This observation raises the ques-
tion of whether microRNAs present in RBCs are suitable for use
as biomarkers, even if they are often expressed at high levels
in certain tissues or overexpressed in solid tumors. The enrich-
ment of these microRNAs in RBCs complicates the interpretation
of biomarker studies as it is difficult to discriminate between
presence of a microRNA in the circulation due to controlled
release from the tissue of origin (e.g., microvesicles), mechani-
cal rupture of cells (e.g., ischemia) and the changes introduced by
hemolysis.
Hemolysis may occur in vivo as part of the underlying dis-
ease process, or (more commonly) as a complication of the
collection and processing of blood. Hematological malignancies
such as chronic lymphocytic leukemia can result in autoimmune
hemolysis (Rytting et al., 1996), while metastatic solid cancers can
be associated with microangiopathic hemolysis and disseminated
intravascular coagulation (Lohrmann et al., 1973; Rytting et al.,
1996; Lechner and Obermeier, 2012). In addition, a number of
drugs – in particular chemotherapeutic drugs – can influence the
normal structure of RBCs (Dumez et al., 2004; Schauf et al., 2004),
and render the cell vulnerable to damage as it passes through
the microvasculature. This in turn can result in release of RBC
intracellular contents, and therefore has the potential to increase
RBC-enriched microRNAs in the plasma. However, these are all
relatively rare events which in most patients would not be expected
to contribute to a significant increase in RBC-related microRNAs.
Besides the possibility of disease- or drug-associated hemolysis
resulting in an increase in levels of RBC-enriched microRNAs,
disease-related anemia has the potential to result in changes in
the levels of potential biomarker microRNAs in plasma/serum.
A number of studies have reported a decrease in levels of candi-
date microRNA biomarkers in cancer, which is somewhat coun-
terintuitive. For example, reduced levels of the RBC-enriched
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Table 4 | Proposed biomarker microRNAs.
miRNA Disease Regulation Reference Affected by hemolysis
miR-103 MPM Down (compared to asbestos-exposed
and healthy)
Weber et al. (2012) No
Pancreatic cancer (PC) Up (compared to healthy) Ren et al. (2012)
miR-106a Gastric cancer (GC) Up (compared to healthy) Tsujiura et al. (2010) Yes
miR-122 Hepatitis B virus (HBV)-related
hepatocellular carcinoma (HCC)
Up (compared to healthy) Zhou et al. (2011) No
Hepatitis B Up (compared to healthy) Zhang et al. (2010)
Liver injury (mouse model) Up (compared to no injury) Zhang et al. (2010)
miR-126 MPM Down (compared to healthy and
NSCLC)
Santarelli et al. (2011),
Tomasetti et al. (2012)
No
Abdominal aortic aneurysm (AAA) Down (compared to healthy) Kin et al. (2012)
miR-146a Esophagitis Up (compared to healthy) Lu et al. (2012a) No
PC Down (compared to healthy) Ali et al. (2010)
miR-155 AAA Down (compared to healthy) Kin et al. (2012) No
Esophageal cancer Down (compared to healthy) Liu et al. (2012)
Breast cancer Up (compared to healthy) Lu et al. (2012b)
miR-16 Traumatic brain injury Up (compared to healthy) Redell et al. (2010) Yes
Myelodysplastic syndrome Up (compared to healthy) Zuo et al. (2011)
miR-17 Endometriosis Down (compared to healthy) Jia et al. (2013) Yes
GC Up (in later stages) Wang et al. (2012)
GC Up (compared to healthy) Tsujiura et al. (2010)
miR-21 PC Up (compared to healthy) Ali et al. (2010) Yes
GC Up (compared to healthy) Tsujiura et al. (2010)
HBV-related HCC Up (compared to healthy) Zhou et al. (2011)
Esophagitis Up (compared to healthy) Lu et al. (2012a)
miR-210 PC Up (compared to healthy) Wang et al. (2009) Yes
Kidney injury Up (compared to healthy) Lorenzen et al. (2011)
miR-223 NSCLC Down (in later stages) Heegaard et al. (2012) No
AAA Down (compared to healthy) Kin et al. (2012)
Esophagitis Up (compared to healthy) Lu et al. (2012a)
HBV-related HCC Down (compared to healthy) Zhou et al. (2011)
miR-27a HBV-related HCC Down (compared to healthy) Zhou et al. (2011) No
miR-29a CRC Up (compared to healthy) Huang et al. (2010) No
miR-31 Breast cancer Up (compared to healthy) Lu et al. (2012b) No
miR-451 GC Up (compared to healthy) Konishi et al. (2012) Yes
miR-625-3p MPM Up (compared to healthy and
asbestosis)
Kirschner et al. (2012) No
miR-720 Multiple myeloma Up (compared to healthy) Jones et al. (2012) No
miR-92a CAD Down (compared to healthy) Fichtlscherer et al. (2010) Yes
Non-Hodgkin’s lymphoma Down (compared to healthy) Ohyashiki et al. (2011)
Multiple myeloma Down (compared to healthy) Yoshizawa et al. (2012)
CRC Up (compared to healthy) Huang et al. (2010)
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FIGURE 5 | Effect of hemolysis on biomarker candidates. Five proposed
biomarker candidates were identified to be changing with increased
hemolysis in (A) the RBC dilution series and (B) the six matching pairs of
hemolyzed and non-hemolyzed plasma. Another nine proposed biomarkers
remained unaffected by increasing hemolysis in both the dilution series (C)
and the matched pairs (D). The red line represents the relative expression of
the corresponding non-hemolyzed samples. Data are presented as raw Cq
value±SD (A,C) or relative microRNA level±SD (B,D).
miR-92a were reported to have diagnostic potential in hematolog-
ical malignancies, while levels of this microRNA are increased in
the corresponding malignant cells (Tanaka et al., 2009; Ohyashiki
et al., 2011; Yoshizawa et al., 2012). In addition miR-126, another
microRNA present at high levels in RBCs was found to be reduced
in plasma from MPM patients (Santarelli et al., 2011; Tomasetti
et al., 2012), a disease in which anemia is a relatively frequent
occurrence. It is tempting to speculate that this somewhat sur-
prising discrepancy between plasma and cell levels of miR-92a
in leukemia, and the decrease of miR-126 in MPM, results from
reduced levels of RBCs as a result of cancer-related anemia in those
patients.
More commonly hemolysis occurs during blood collection and
sample processing. Hemolysis has been reported in up to 42.6%
of general medical hospital inpatients (free hemoglobin>0.5 g/l),
but only 5.6% when using visual inspection (Lippi et al., 2009;
Hawkins, 2010). Causes of sample hemolysis include venous sta-
sis, phlebotomist experience and site of collection (Lippi et al.,
2005; Hawkins, 2010). Using spectrophotometry we have detected
significant hemolysis in approximately 15% of collected samples
(often in the absence of color change in plasma/serum visible to
the eye). Hemolysis may be an under-reported and important con-
tributor to changes in microRNA levels in plasma or serum. The
relative importance of a technical cause of hemolysis should be
considered in the context of two different scenarios: biomarker
discovery and diagnostic testing. In the case of studies aiming
to identify microRNAs as diagnostic or prognostic markers for
a disease, the effect of hemolysis may be limited as one would
expect that hemolysis occurring during blood taking or plasma
processing would affect equal numbers of samples in both case and
control groups. Thus, variations introduced by in vitro hemolysis
should therefore be present in any sample series investigated and
not influence the identification of potential biomarkers. How-
ever, the large variations in abundance of microRNA biomarkers
reported in a number of studies might be a result of the inclusion
of hemolyzed samples. This speculation is supported by our own
experience; when excluding hemolyzed plasma from our sample
series we find a significant reduction in variability in levels of
RBC-microRNA (Kirschner et al., 2011) and also see a lower vari-
ability in the levels of potential diagnostic markers (Kirschner et al.,
2012) than those reported by others (Ng et al., 2009; Heneghan
et al., 2010; Huang et al., 2010; Devaux et al., 2012). Together,
these observations suggest that a quantification of hemolysis in
samples should be included in any study of a potential biomarker
candidate.
Although hemolysis is likely to represent only a minor con-
founding factor in biomarker discovery studies, the situation is
different once a microRNA is actually confirmed as a marker for
a specific disease and used as a diagnostic/prognostic tool. In this
setting, where for instance a single sample is analyzed to deter-
mine presence or absence of disease, hemolysis can significantly
impact on the result, especially if the microRNA used as marker
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Table 5 | Subsets of biomarker-endogenous control candidates.
microRNAs changing with hemolysis microRNAs unaffected by hemolysis
microRNA Relative fold increase H vs. NH microRNA Relative fold difference H vs. NH
N1 MPM1 N1 MPM1
let-7b 2.12±0.43 14.06±9.83 let-7a 1.33±1.3 1.25±0.71
miR-126# 2.70±1.03 2.87±1.00 let-7d 1.49±0.77 0.97±0.78
miR-140-3p 2.60±0.70 10.96±3.69 miR-1260 1.37±1.14 1.23±0.52
miR-15a# 2.92±1.96 2.00±1.10 miR-127 1.29±0.68 0.66±0.86
miR-15b# 5.40±4.17 4.96±2.04 miR-1274A 1.14±0.27 1.20±0.59
miR-16 3.55±0.87 10.18±0.38 miR-1274B 1.49±0.39 0.87±0.06
miR-193b 5.26±3.39 6.16±6.00 miR-130b 1.00±0.38 1.10±0.33
miR-194 18.14±14.34 2.86±2.21 miR-142-5p 1.50±1.04 1.30±0.43
miR-20a 2.10±0.83 3.83±0.37 miR-143 0.89±0.47 1.09±0.32
miR-20b 2.46±1.80 19.24±3.30 miR-146a 1.29±0.14 1.49±0.87
miR-21 2.57±0.47 2.90±0.22 miR-221 1.35±0.58 1.50±0.93
miR-210 2.50±1.01 26.93±7.48 miR-222 1.26±0.45 1.38±0.06
miR-26b 2.56±0.48 3.58±1.29 miR-27b 1.49±1.40 1.27±0.21
miR-320 2.25±0.13 3.32±0.01 miR-324-5p 1.20±0.04 1.08±0.90
miR-320B 2.28±0.96 3.66±3.50 miR-338-5P 0.76±0.06 1.41±0.77
miR-324-3p 3.30±1.51 9.12±6.61 miR-339-5p 1.29±0.94 1.04±0.16
miR-331-5p 3.54±3.40 22.65±19.81 miR-340# 0.94±0.38 0.8±0.53
miR-340 2.63±1.43 3.71±1.20 miR-425# 1.10±0.83 0.96±0.02
miR-425-5p 2.44±0.90 4.75±3.74 miR-744 0.71±0.21 1.01±0.31
miR-454 4.62±1.19 6.15±3.64
miR-484 2.11±0.12 3.13±0.09
miR-486-3p 2.51±1.32 14.20±5.57
miR-532-3p 2.50±2.05 3.75±2.71
miR-652 3.08±2.52 3.45±0.43
miR-140 2.17±0.18 3.20±0.56
miR-451 2.38±0.84 15.27±1.78
is hemolysis-susceptible. As the clinical application of microRNAs
as diagnostic/prognostic markers is the ultimate aim of the discov-
ery studies currently performed, it is essential that these potential
confounders are taken into consideration, and hemolysis needs
to be quantified as part of the quality control process. While
appropriate methods for normalization of microRNA expression
data [generally obtained through real-time quantitative PCR (RT-
qPCR)] could potentially overcome the problems associated with
hemolysis-related variability, the normalization of plasma/serum
microRNA data has yet to be standardized. The problem of nor-
malization has been addressed in many studies as it is often
not possible to accurately quantify RNA concentration, with the
result that using equal amounts of RNA as input into the reac-
tions is mostly impossible (Brase et al., 2010; Reid et al., 2011;
Zampetaki and Mayr, 2012). A frequently used alternative is
to spike-in known amounts of exogenous microRNAs (such as
C. elegans miRs) during the isolation process (Mitchell et al.,
2008). This approach certainly has the potential to account for
differences in RNA isolation efficiency between different sam-
ples, but it is not able to account for differences introduced by
hemolysis. Based on the profiling data in the present study, we pro-
pose the possibility of selecting a biomarker and an appropriate
endogenous control from subsets of microRNAs affected equally
by hemolysis. Our pilot study identified two potential subsets,
one with microRNAs unaffected by hemolysis and one with
hemolysis-susceptible microRNAs. Such an approach can serve
as a starting point for further in-depth validation in a much larger
sample set.
In summary, our data provide further evidence that hemolysis
has a substantial impact on a large number of cell-free microRNAs
in plasma and serum, many of which are being investigated as
potential biomarkers of disease. These data suggest that future
investigations of cell-free microRNA biomarkers should care-
fully assess hemolysis and the effect it has on a biomarker
candidate.
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